SG11201603506PA - Treatment of damaged nerve with pten inhibitor - Google Patents

Treatment of damaged nerve with pten inhibitor

Info

Publication number
SG11201603506PA
SG11201603506PA SG11201603506PA SG11201603506PA SG11201603506PA SG 11201603506P A SG11201603506P A SG 11201603506PA SG 11201603506P A SG11201603506P A SG 11201603506PA SG 11201603506P A SG11201603506P A SG 11201603506PA SG 11201603506P A SG11201603506P A SG 11201603506PA
Authority
SG
Singapore
Prior art keywords
treatment
damaged nerve
pten inhibitor
pten
inhibitor
Prior art date
Application number
SG11201603506PA
Other languages
English (en)
Inventor
Kwan Hee Lee
Moon Jong Noh
Kwangwood Ahn
Original Assignee
Tissuegene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tissuegene Inc filed Critical Tissuegene Inc
Publication of SG11201603506PA publication Critical patent/SG11201603506PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03067—Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase (3.1.3.67)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
SG11201603506PA 2013-11-04 2014-11-04 Treatment of damaged nerve with pten inhibitor SG11201603506PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361899795P 2013-11-04 2013-11-04
PCT/US2014/063900 WO2015066701A1 (en) 2013-11-04 2014-11-04 Treatment of damaged nerve with pten inhibitor

Publications (1)

Publication Number Publication Date
SG11201603506PA true SG11201603506PA (en) 2016-05-30

Family

ID=53005300

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201603506PA SG11201603506PA (en) 2013-11-04 2014-11-04 Treatment of damaged nerve with pten inhibitor

Country Status (9)

Country Link
US (2) US10584153B2 (ja)
EP (1) EP3066116B1 (ja)
JP (1) JP6483115B2 (ja)
KR (2) KR102405411B1 (ja)
CN (1) CN105873942B (ja)
AU (1) AU2014341899B2 (ja)
CA (1) CA2929483C (ja)
SG (1) SG11201603506PA (ja)
WO (1) WO2015066701A1 (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018103038A1 (zh) * 2016-12-08 2018-06-14 拜西欧斯（北京）生物技术有限公司 一种缀合物及其应用
IL314908A (en) 2018-03-29 2024-10-01 Technion Res & Dev Foundation Bubbles containing PTEN inhibitor and their uses
KR20200080554A (ko) * 2018-12-27 2020-07-07 가톨릭관동대학교산학협력단 Ebp50을 포함하는 말초신경손상 치료용 조성물
JP7320399B2 (ja) 2019-08-06 2023-08-03 ジャパンマリンユナイテッド株式会社 構造物の接着方法及び接着構造
AU2021393526A1 (en) * 2020-12-04 2023-07-06 Kolon Tissuegene, Inc. Treatment of spinal cord injury with pten inhibitor
WO2023223312A1 (en) 2022-05-15 2023-11-23 Nurexone Biologic Ltd. Anti-pten rna interference oligonucleotides and uses thereof
CN116769037B (zh) * 2022-09-14 2024-09-10 嘟乐士生物制药(河北)股份有限公司 包含胶原蛋白的抗衰老组合物及其在早衰中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009117387A2 (en) * 2008-03-17 2009-09-24 The Trustees Of Columbia University In The City Of New York Methods to treat neurodegenerative conditions or diseases by targeting components of a pten signaling pathway
DK2502623T3 (en) * 2008-06-06 2016-07-04 Children's Medical Center Corp Promoting axonregeneration the adult cns by management of protein translation
JP5517078B2 (ja) * 2009-04-09 2014-06-11 国立大学法人 宮崎大学 Ｐｔｅｎのリン酸化抑制剤又は脱リン酸化剤
KR20100121710A (ko) * 2009-04-30 2010-11-18 한국과학기술원 Ｐｔｅｎ의 기능 복구 및 ｐｔｅｎ을 투여하는 단계를 포함하는 망막 변성 예방 또는 치료 방법
CA2777628C (en) * 2009-10-16 2019-12-03 The University Of British Columbia Inhibitors of phosphatase and tensin homolog (pten) compositions, uses and methods
EP2773382A4 (en) * 2011-11-01 2016-03-23 Childrens Medical Center CO-ACTIVATION OF MTOR AND STAT3 PATHWAYS TO PROMOTE NEURONAL SURVIVAL AND REGENERATION

Also Published As

Publication number Publication date
KR20160091347A (ko) 2016-08-02
JP2017500283A (ja) 2017-01-05
US20200270319A1 (en) 2020-08-27
AU2014341899A1 (en) 2016-06-16
JP6483115B2 (ja) 2019-03-13
CN105873942B (zh) 2020-12-29
CA2929483C (en) 2021-11-23
KR20180095085A (ko) 2018-08-24
EP3066116A4 (en) 2017-04-26
AU2014341899B2 (en) 2018-12-13
KR102405411B1 (ko) 2022-06-08
US20160340396A1 (en) 2016-11-24
EP3066116A1 (en) 2016-09-14
EP3066116B1 (en) 2021-12-01
CA2929483A1 (en) 2015-05-07
CN105873942A (zh) 2016-08-17
KR102086886B1 (ko) 2020-03-10
US10584153B2 (en) 2020-03-10
WO2015066701A1 (en) 2015-05-07

Similar Documents

Publication Publication Date Title
HK1217908A1 (zh) 治療膽管癌的方法
HK1218506A1 (zh) 治療黑素瘤的方法
IL252547A0 (en) Treatment of multiple sclerosis using laquinimod
SG11201508223YA (en) Treatment of cancer with dihydropyrazino-pyrazines
ZA201507733B (en) Treatment of cancer with dihydropyrazino-pyrazines
HK1224324A1 (zh) 煤處理
SG11201603506PA (en) Treatment of damaged nerve with pten inhibitor
HK1224307A1 (zh) 原毒素- 變體及其使用方法
HK1218254A1 (zh) 用拉喹莫德治療多發性硬化症
HK1222339A1 (zh) 金屬-β-內酰胺酶的抑制劑
IL240763B (en) The halopyrazoles as thrombin inhibitors
IL241096B (en) Treatment methods
GB201607581D0 (en) Treatment of cancer
HK1232118A1 (zh) 癌症的治療
GB2525530B (en) Treatment of hard surfaces
AU2013901359A0 (en) Methods of Treatment
GB201322778D0 (en) Method of treatment
GB201314882D0 (en) Method of treatment
GB201320653D0 (en) Treatment of plants
GB201306411D0 (en) Treatment of inflammatory conditions
AU2013902652A0 (en) Treatment of minerals
GB201322347D0 (en) Treatment of cancer
GB201318742D0 (en) Treatment of cancer
AU2013904170A0 (en) Method of treatment
GB201308529D0 (en) Treatment of cancer